Appendix S1:

Phase 1 invitation:

Thank you for taking part in this Delphi study.

The study consists of three rounds:

1. **Round 1: Exploratory Phase**
    - The questions in the Delphi seek to specify parameters which are essential for the teledermatologist in choosing the right action on behalf of the general practitioner.
    - Initial suggestions and comments will help gather a comprehensive set of perspectives.
2. **Round 2: Prioritization Phase**
    - Rating the importance of various variables for teledermatological assessment.
    - Identifying key elements while removing less critical ones.
3. **Round 3: Refinement and Consensus Phase**
    - Reviewing and refining the list of prioritized variables.
    - Achieving consensus on the most essential components for teledermatological evaluations.

Your expertise is invaluable as we seek to establish consensus on the essential components for teledermatological assessments of skin tumors. Your responses will directly influence the development of effective teledermatological referrals which allows for efficient and accurate teledermoscopy-based diagnostic and management strategies.

Key Opinion Leaders (KOLs) are estimated to spend 30 minutes per round.
There is a 30-day response limit in each round. Participants are reminded up to two times on days 15 and 25. Extensions can be granted by the steering group in extraordinary situations (in case of vacations, sickness etc.) to improve the response rate. KOLs not responding during one round are excluded and not invited for subsequent rounds. One month for data processing in between rounds is expected.

The panel of KOLs commits to the entirety of the Delphi process by accepting participation in the study. KOLs are accredited as a group-author "expert panel" with specification of panel members under Acknowledgements in the published paper

Appendix S2:

Phase 2 invitation:

Second-Round Survey for Delphi Study on Teledermatology and Dermoscopy: Consensus on Essential Components for Teledermatological Assessment of Skin Tumors

Thank you for participating in this Delphi study. Your expertise is invaluable in helping us establish consensus on the essential variables for teledermatological assessments of skin tumors. Your insights will directly contribute to developing effective teledermatology referral systems and optimizing teledermoscopy-based diagnostic and management strategies.

In Phase 2, we aim to build upon the findings from Phase 1 by focusing on the variables that are essential for dermatologists to make an accurate diagnosis. General practitioners work under tight time constraints, so your task is to ensure that the referral process is streamlined, including only the most critical information that directly impacts teledermatological decision-making.

Your Role as a Key Opinion Leader (KOL):
You will review a list of variables derived from Phase 1, categorized as follows:

1. Patient Information
2. Lesion Information
3. Visual Modalities

Rating Process:
Each variable should be rated using a 5-point Likert scale based on the following criteria:

- Essentiality: How crucial the variable is for a precise teledermatological assessment.
- Relevance to Patient Outcomes: The impact of the variable on clinical decisions and patient care.
- Feasibility: The practicality of obtaining and utilizing the information in real-world settings, particularly from a general practitioner's perspective.

Scoring Guidelines:

- Each variable will receive an average score based on your ratings.
- Variables with an **average score below 3.5** will be considered for **exclusion**.
  eg:
    - A score of 5, 5, and 1 results in an average of 3.6.
    - A score of 5, 4, and 1 results in an average of 3.3.
- Variables scoring 3.5 or higher will advance to Phase 3 for further review.

Important Instructions:
Please focus on selecting variables that are truly essential for teledermatological assessments, rather than including variables out of caution or to cover all possible scenarios.

Rating Scale:
1 = Strongly Disagree
2 = Disagree
3 = Neither Agree nor Disagree

4 = Agree
5 = Strongly Agree

Submission Deadline:
Please complete and submit your responses by January 15, 2025.

If you have any questions or encounter any issues, feel free to contact Alexander Detlefsen at aldet16@student.sdu.dk. Reminder emails will be sent 14 and 28 days after the initial invitation.

Thank you for your valuable contribution to shaping the future of teledermatology and dermoscopy.

Appendix S3:

Phase 3 invitation:

Third-Round Survey for Delphi Study on Teledermatology and Dermoscopy: Consensus on Essential Components for Teledermatological Assessment of Skin Tumors

Thank you for participating in this Delphi study. In this final phase, the focus is on reaching consensus on the variables identified as essential during the second round.

We encourage you to be highly critical in your ratings, aiming for a significant reduction in the number of variables so that only the most essential components are retained for a precise and focused teledermatological assessment.

Please evaluate whether the information already visible in the image material provided in referrals still needs to be explicitly included among the voted variables. Keep in mind that these variables will, in most cases, need to be provided by primary care physicians. Prioritize minimizing redundancy and reducing the workload on general practitioners.

Variable Elimination:
Only variables supported by at least two-thirds of the Key Opinion Leaders (KOLs) will be included in the final list. This ensures that the final consensus reflects broad agreement among the panel.

Submission Deadline:
Please complete and submit your responses by March 7th, 2025. If you have any questions or encounter any issues, feel free to contact Alexander Detlefsen at aldet16@student.sdu.dk.

Thank you for your valuable contribution to shaping the future of teledermatology and teledermoscopy.

Anonymity and Unbiased Contributions:
Throughout the process, the anonymity of KOLs is maintained to prevent bias. Responses remain anonymized among panel members and the steering group, except for the data manager. KOLs will be collectively credited as a group-author "expert panel".